Here’s a shocking revelation: the pharmaceutical giant behind blockbuster weight-loss drugs Wegovy and Ozempic is bracing for a steep revenue plunge in 2026. But why is this happening, and what does it mean for the future of weight-loss treatments? Let’s dive in.
Novo Nordisk, the Danish company once hailed as the poster child for the booming weight-loss drug market, has forecast a staggering 5% to 13% drop in sales this year. This comes despite the highly anticipated U.S. launch of its new Wegovy pill—a development that, on paper, should have been a game-changer. Yet, the company’s share price nosedived 18% on Wednesday morning, wiping out all year-to-date gains and capping a brutal 50% decline over the past year. And this is the part most people miss: it’s not just one factor causing this downfall—it’s a perfect storm of challenges.
First, there’s the Trump administration’s aggressive push to slash drug prices in the U.S., which forced Novo Nordisk to cut the cost of its medications from over $1,000 a month to an average of $350. While this move aims to make treatments more accessible, it’s squeezing the company’s profit margins. Then there’s the looming threat of patent expirations for semaglutide, the key ingredient in both Wegovy and Ozempic, in countries like India. This opens the door for generic drugmakers to produce cheaper alternatives, further intensifying competition.
But here’s where it gets controversial: while Novo Nordisk will retain patent protection for semaglutide in Europe and Japan until 2033 and in the U.S. until 2032, the company’s CEO, Mike Doustdar, remains optimistic. He highlights the strong early uptake of the Wegovy pill in the U.S., with 50,000 prescriptions per week by late January, and expresses confidence in driving volume growth. But is this enough to offset the headwinds? Critics argue that the company’s recent job cuts—9,000 positions axed in 2025—signal deeper troubles, especially as rivals like Eli Lilly gain ground with competing treatments like Mounjaro, which clinical studies suggest may lead to greater weight loss.
Speaking of Eli Lilly, the race to dominate the GLP-1 market is heating up. Novo Nordisk’s Wegovy pill is the first oral GLP-1 medication on the market, but Lilly is expected to launch its own pill this spring, pending regulatory approval. These drugs work by mimicking the gut hormone GLP-1, reducing appetite and promoting feelings of fullness. With the global GLP-1 market projected to expand, Novo Nordisk is betting on new treatments, including higher doses of Wegovy, to stay competitive.
Here’s a thought-provoking question: Can Novo Nordisk reclaim its dominance in a market it once ruled, or will rising competition and pricing pressures push it further into decline? Darren Nathan, head of equity research at Hargreaves Lansdown, notes that while the Wegovy pill’s launch was strong, Doustdar faces tough questions as he navigates this turbulent landscape. Meanwhile, GSK, Britain’s second-largest drugmaker, has also tempered its sales growth forecast to 3%-5% this year, citing similar challenges, including its own deal with the Trump administration to lower drug prices.
GSK’s new CEO, Luke Miels, remains bullish, reaffirming the company’s £40 billion-plus sales target by 2031 and emphasizing increased investment in research and development. But with 52% of its sales coming from the U.S., GSK is equally vulnerable to policy shifts from the White House. What do you think? Is this the beginning of a new era in pharmaceutical pricing, or a temporary setback for industry giants? Share your thoughts in the comments—let’s spark a conversation!
